Prilenia Achieves Last Patient Last Visit in Phase 3 PROOF-HD Clinical Study for Huntington’s Disease

From Huntington Study Group: Prilenia Therapeutics B.V., a clinical stage biotechnology company, met a milestone that the last participant in PROOF-HD, a global Phase 3 study in Huntington’s disease (HD), has completed the last planned visit of the blinded treatment period, marking the completion of the main study.  Topline results of the PROOF-HD study are expected in early Q2 2023.

Check out their post to learn more about the study:

Categories: Uncategorized